SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Person › Details

Haude Costa (France Biotech)

Costa, Haude (France Biotech 201412)


Organisation Organisation France Biotech
Products Product BIOTECH
  Product 2 business development (state/region)

France Biotech. (12/18/14). "Press Release: France Biotech Presents the Results of Its Twelfth Annual Survey, »Panorama of the Life Sciences«". Paris.

> A dynamic industry that has entered a mature stage;

> More and more international successes;

> Spectacular backing by stock markets;

> Funding issues for small companies struggling to develop their activities.

> France Biotech reiterates its recommendations to foster excellence in the industry

France Biotech, an association of entrepreneurs in the life sciences industry, publishes the twelfth edition of its annual survey, « Panorama of the Life Sciences® », which outlines the industry’s major trends for 2013 and 2014 in France and worldwide. This year, 214 French companies took part in the study.

“Our twelfth study highlights the dynamism and wealth of French innovation in the life sciences, from medical devices to therapeutics, and green biotechnologies. Our SMEs have a very high level of technical expertise and efficiency, allowing them to quickly bring numerous projects to advanced stages of development. This wealth has convinced stock market investors to invest in our industry, a unique phenomenon in Europe that rewards SMEs founded in the 2000s. These success stories belong to outstanding entrepreneurs and their venture capital investors, and are a sign of both maturity and promising growth potential.

However, our youngest companies are struggling; venture capital investors are fewer and have less power than they used to. The entire funding chain is fragile, and the serious lack of incentives to channel French household savings toward innovative companies can’t be fully compensated by the efforts of Bpifrance (a public investment bank),” said Pierre-Olivier Goineau, President of France Biotech.

“In order for our innovations to stir economic growth and job creation, some obstacles blocking our way ought to be removed. These include excessive paperwork and administrative tasks when dealing with multiples layers of academic institutions; delays in applying to CIR (the Research Tax Credit, a French tax incentive mechanism to support investments in SMEs); a lack of understanding of the specificities of our industry from the ANSM (the French Agency for the Safety of Health Products, whose task is to assess the risks posed by new health products); scarcity of the dialogue with the public health authorities; suppression of the Precautionary Principle that generates fears,” said M. Goineau.

France Biotech reiterates its recommendations to implement an ambitious policy to promote the development of innovative companies in the life sciences

> Placing the innovation in life sciences at the heart of public health policies;

> Strengthen and develop the number of venture capital investment funds by channeling 5% of the French households’ life insurance toward investments into innovative companies;

> Adapt the lifespan of FCICs (a French form of mutual fund) and the status of JEI (a program supporting innovative companies’ R&D investments, including through tax breaks) to our investment cycle, which is longer than in other sectors, a disadvantage made worse by the current status quo;

> To promote the hiring of young academics using CIR and the JEI status;

> To foster contractual agreements with our academic partners by streamlining the current practices and removing the multiple layers of supervision by various academic institutions;

> To improve our competitiveness by lowering taxes related to BSAs (stock warrants) and by extending the BSPCEs (founders' warrants) to all SMEs.

About the Panorama of the Life Sciences Industry study

Since 2002, France Biotech has conducted the Panorama of the Life Sciences Industry in France, a unique study that provides an annual update on the growth and dynamism of this innovative sector in France. The results of this study allow France Biotech to ground its proposals to the government in hard facts and to effectively represent the entire industry. The Panorama analyses data from independent companies allocating at least 15% of total spending to Research and Development costs. France Biotech surveyed more than 400 companies via a secure online questionnaire and has analyzed the data provided from 186 of the 192 total responses. The results of this survey will remain the property of France Biotech.

About Life Sciences in France

A second generation of Life Sciences companies has arrived in France in recent years. Over 250 companies in the Life Sciences exist, consisting of four main types of businesses. Therapeutics companies remain the most numerous, followed closely by diagnostic and medical devices companies, while an emergence of companies in the fields of cosmetics and the environment has occurred in recent years.

About France Biotech

France Biotech brings together the main French life science companies and their expert partners. Its mission is to support the development of the French life sciences by advocating for a favorable regulatory and fiscal environment. In 2004, France Biotech successfully lobbied the French government to create a special fiscal status for innovative start-ups and continues to act as an advocate for the French innovative sector. The organization is currently chaired by Pierre-Olivier Goineau, Co-Founder and CEO of ERYTECH Pharma. France Biotech has over 150 members and its board of directors is composed of 20 entrepreneurs in the life sciences.

France Biotech contact information:

France Biotech
Haude Costa
Tel : 01 56 58 10 70 / 06 84 25 88 27

Press contact information in France:
Alize Public Relations
Caroline Carmagnol and Sophie Colin
Tel : 01 44 54 36 66 / 06 31 13 76 20

Record changed: 2015-10-18


Picture [LSUS] – The Business Web Portal 600x60px

More documents for Haude Costa

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px

» top